Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 12.92% |
| 10 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | 16.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.87% |
| Mar 31, 2026 | -923.59% |
| Dec 31, 2025 | 200.59% |
| Sep 30, 2025 | -152.34% |
| Jun 30, 2025 | 114.68% |
| Mar 31, 2025 | -83.33% |
| Dec 31, 2024 | -304.67% |
| Sep 30, 2024 | 514.74% |
| Jun 30, 2024 | -86.32% |
| Mar 31, 2024 | 456.68% |
| Dec 31, 2023 | -57.75% |
| Sep 30, 2023 | 165.27% |
| Jun 30, 2023 | -25.63% |
| Mar 31, 2023 | 102.05% |
| Dec 31, 2022 | 152.89% |
| Sep 30, 2022 | -104.14% |
| Jun 30, 2022 | -201.20% |
| Mar 31, 2022 | -444.52% |
| Dec 31, 2021 | -284.79% |
| Sep 30, 2021 | 198.75% |